New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Novo Nordisk A/S

NVO

Healthcare Drug Manufacturers General

Novo Nordisk A/S’s revenue for fiscal 2025 (year ended December 2025) was $46.8 billion, up 11.1% from fiscal 2024.

Revenue
+3.87%
EPS
−17.1%
Free cash flow
−14.8%
Total debt
+30.7%

Quarter to September 2026, against a year earlier

38.57 0.32 −0.82%
Market cap
$128.6B
P/E
9.8×
Fwd P/E FY26e
—
Dividend yield
4.62%
F-score
5/9
ROIC
29.6%
Net debt / EBITDA
0.7×
Payout ratio
0.5×

Novo Nordisk A/S (NVO) EV/Sales

Alert me on EV/Sales

As of Nov 19, 2026, Novo Nordisk A/S (NVO) trades at a EV/Sales of 3.6×. Over the past ten years it has ranged from 3.4× (October 2026) to 18.5× (June 2024); the current reading is higher than 1% of that period. That is below the Drug Manufacturers General industry median of 4.1× and above the Healthcare sector median of 3.3×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 5.1× (44.90%)
FY2024 9.3× (31.06%)
FY2023 13.5× 9.45%
FY2022 12.4× 7.30%
FY2021 11.5× 37.92%
FY2020 8.4× 12.71%
FY2019 7.4× 16.26%
FY2018 6.4× (17.32%)
FY2017 7.7× 46.14%
FY2016 5.3× (42.05%)

Quarterly newest first

Period EV/Sales Change
Sep 2026 3.5× (21.27%)
Jun 2026 4.4× 23.29%
Mar 2026 3.6× (30.52%)
Dec 2025 5.1× (6.09%)
43 more quarters

Against its own ten years

Low 3.4× High 18.5×
Ten-year median 8.1×
Current reading's percentile 1

EV/Sales against peers

Company EV/Sales
SNY Sanofi compare 2.1×
GSK GSK PLC Sponsored ADR compare 2.8×
BMY Bristol Myers Squibb Company compare 3.0×
PFE Pfizer Inc. compare 3.2×
NVO Novo Nordisk A/S 3.6×
AZN AstraZeneca PLC compare 4.7×
NVS Novartis AG compare 5.6×
AMGN Amgen Inc. compare 7.2×
GILD Gilead Sciences, Inc. compare 7.3×
Drug Manufacturers General industry median 4.1×
Healthcare sector median 3.3×
Market median 2.0×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on NVO